Results showing GABA’s relevance for diabetes, patent filed by Diamyd Medical and Uppsala University scientist, published in eBioMedicine

Diamyd Medical holds, in collaboration with Professor Bryndis Birnir at Uppsala University, patent pending new GABA results. The results, now published in the scientific journal eBioMedicine, supports GABA’s role as a therapeutic important signal substance in the insulin producing beta cells and in immune cells from healthy humans as well as from patients with type 1 and type 2 diabetes.The results, published in two separate articles, identify new biomarkers and support the therapeutic effect of GABA treatment in humans. In the first article, an international research team lead by Professor